Boehringer Ingelheim has announced the appointment of Dr Mehdi Shahid as corporate senior vice president of medicine and chief medical officer, effective March 1, 2019.
Current global head of medicine in the oncology therapeutics area of the company, Dr Shahidi will follow Dr Thor Voigt who is set to retire after 27 years of service at the end of April 2019.
Dr Shahidi joined Boehringer Ingelheim in 2005 as a clinical development lead for oncology, where over the following years he assumed broader responsibilities in the Oncology TA in clinical development and medical affairs. In 2016 he became global head of medicine, oncology.
He is a UK qualified clinical oncologist, who obtained his medical degree in Tehran, and completed his specialist oncology training at the Royal Marsden Hospital, London.
Prior to joining the pharmaceutical industry, he had a successful clinical and research career, and as a registered specialist in Pharmaceutical medicine, he brings a wealth of insights working with patients and the broader healthcare community to the company.
Allan Hillgrove, member of the board of managing directors with responsibility for the Human Pharma Business Unit said: “In the pharmaceutical industry, the medical function is at the core of our success, which is based on the improvement we can provide to the health of patients.
“We are fortunate to have many strong leaders in this area, and thank Dr Voigt for his excellent contributions. He will have a great successor in Dr Shahidi who takes over this important role as chief medical officer with a well-deserved, excellent reputation inside and outside our company.”
